Denmark· DK-28106307819

Lismay

A qj01ff52 product containing lincomycinhydrochlorid, spectinomycinsulfat, registered in Denmark by Laboratorios Maymo S.A.U..

ATC QJ01FF52

Checked against Danish Medicines Agency (Denmark) on

Informational only — not a medical device.

SOURCE REGISTER · DKDanish Medicines Agency (Denmark)normalisedLismayATCQJ01FF52REGISTER NO.DK-28106307819PACKS LISTED1CHECKEDSeptember 30, 2026

The record

At a glance

Danish Medicines Agency (Denmark)
Active substance
Lincomycinhydrochlorid, Spectinomycinsulfat
Manufacturer
Laboratorios Maymo S.A.U.
Country
Denmark (DK)
ATC code
QJ01FF52
ATC class
QJ01FF52
Reimbursed
Not published by this register
Source register
Danish Medicines Agency (Denmark)
Last checked
September 30, 2026

Packs & prices · 1

  • dk_varenummer
    28106307819

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Danish Medicines Agency (Denmark). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/5ba51f63-bdfe-4c00-a154-d7878235c75d
GET /v1/drugs/5ba51f63-bdfe-4c00-a154-d7878235c75d?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "pulver til anvendelse i drikkevand",
  "source": "dkma",
  "strength": "444,7+222,0 mg/g",
  "auth_role": "CMS",
  "dk_drugid": "28106307819",
  "substance": "Lincomycinhydrochlorid, Spectinomycinsulfat",
  "auth_procedure": "MRP",
  "in_medicinpriser": true,
  "registration_date_serial": "44005"
}

See everything about lincomycinhydrochlorid, spectinomycinsulfat.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.